G20.90
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: - Levodopa treatment for at least 3 months prior to the first measurement - Ability to understand the study procedure - Planned THS surgery for the treatment of idiopathic Parkinson's syndrome - Eligible for MRI measurement - Informed consent, signed and dated by the subject or, in the case of motor impairment, by an independent witness
Exclusion criteria
Exclusion criteria: - Presence of a legally authorized representative - Presence of conditions other than idiopathic Parkinson's disease that may worsen motor or cognitive abilities, such as corticobasal syndrome, multisystem atrophy, dementia, severe arthritis, drug/alcohol abuse, Alzheimer's disease, stroke, or similar conditions - Inability to remain seated in the MEG scanner without involuntary movements producing artifacts - Inability to undergo MRI scanning, e.g., metal implants or tattoos containing metal - Past or present participation in pharmacologic clinical trials related to idiopathic Parkinson's syndrome - Claustrophobia - Unable to tolerate levodopa medication withdrawal for at least 12 hours (including dysphagia, tendency to fall) - Inability to walk
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| i) Evaluation of the sensitivity of active and passive sensor-based assessments to detect changes in clinical/motor symptoms in IPS patients upon treatment with deep-brain stimulation. ii) Investigation of structural and functional neuroimaging correlates as measured using MRI and MEG that underlie generation of PD motor symptoms as measured using sensor-based assessments. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identifying sensor-based assessments that are most sensitive to the effects of levodopa medication. | — |
Countries
Germany
Contacts
Universitätsklinikum Düsseldorf, Institut für Systemische Neurowissenschaften